Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David A. Braun, Kurt C. Demel, Marcus Smith Noel, Hamid Emamekhoo, Julio Antonio Peguero, Rama Balaraman, Ryan H. Moy, Martin Gutierrez, Sunil Sharma, Arif Hussain, Joanna Haas, Daria Chabas, Sue Dasen, Xinyan Zhang, Scott R. Daigle, Ginell Elliott, Sritama Nath, Pavan Kumar, Anita Scheuber, David Sommerhalder
Institutions: Yale University, HealthPartners, Georgetown University, University of Wisconsin–Madison, Columbia University Irving Medical Center, Hackensack University Medical Center, HonorHealth, University of Maryland Medical Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410822625